Invariant chain expression in colon neoplasms

Virchows Archiv

Volumn 435, Issue 1, 1999, Pages 32-36

  Jiang, Zhong ^a   Xu, Minzhen ^b   Savas, Louis ^a   LeClair, Paula ^a   Banner, Barbara F ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Antigen Express Inc   (United States)

Author keywords

Colon neoplasms; HLA DR; Invariant chain

Indexed keywords

CHAPERONE; HLA DR ANTIGEN;

ADENOMA; ARTICLE; CANCER GRADING; CANCER INVASION; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLON CARCINOMA; COLON MUCOSA; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

ADENOCARCINOMA; ADENOMA; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTIGENS, NEOPLASM; COLONIC NEOPLASMS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DR ANTIGENS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING;

EID: 0032790413     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004280050391     Document Type: Article

References (22)

1. 1. Andersen AN, Rognum TO, Lund E, Meling GI, Hauge S (1993) Strong HLA-DR expression in large bowel carcinomas is associated with good prognosis. Br J Cancer 68:80-85
2. 2. Armstrong TD, Clements VK, Martin BK, Ting JPY, Ostrand-Rosenberg S (1997) Major histocompatibility complex class II-transfected tumor cells present endogenous antigens and one potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 94:6886-6891
3. 3. Bertolino P, Rabourdin-Combe C (1996) The MHC class II-associated invariant chain: a molecule with multiple roles in MHC class II biosynthesis and antigen presentation to CD4+ T cells. Crit Rev Immunol 16:359-379
4. 4. Bodmer H, Viville S, Benoist C, Mathis D (1994) Diversity of endogenous epitopes bound to MHC class II molecules limited to invariant chain. Science 263:1284-1286
5. 5. Carbrera T, Ruiz-Cabello F, Garrido F (1995) Biological implication of HLA-DR expression in tumors. Scand J Immunol 41:398-406
6. 6. Ceman S, Sant AJ (1995) The function of invariant chain in class II-restricted antigen presentation. Semin Immunol 7: 373-387
7. 7. Clements VK, Baskar S, Armstrong TD, Ostrand-Rosenberg S (1992) Invariant chain alters the malignant phenotype of MHC class II- tumor cells. J Immunol 149:2391-2396
8. 8. Degener T, Momburg F, Moller P (1988) Differential expression of HLA-DR, HLA-DP, HLA-DQ and associated invariant chain (Ii) in normal colorectal mucosa, adenoma and carcinoma. Virchows Arch 412:315-322
9. 9. Dukes CE (1949) The significance of the unusual in the pathology of intestinal tumor. Am R Coll Surg Engl 4:90-103
10. 10. Dukes CE (1949) The surgical pathology of rectal cancer. J Clin Pathol 2:95-98
11. 11. Graham DM, Appelman HD (1990) Crohn's like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. Mod Pathol 3:332-335
12. 12. Griffin MP, Bergsttralh EJ, Coffey RJ, Beart RW Jr, Melton LJ III (1987) Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer 60:2318-2324
13. 13. Gutierrez J, Lopez-Nevot MA, Cabrera T, Oliva R, Esquivias J, Ruiz-cabello F, Garrido F (1987) Class I and II HLA antigen distribution in normal mucosa, adenoma and colon carcinoma: relation with malignancy and invasiveness. Exp Clin Immunogenet 4:144-152
14. 14. Harrison JC, Dean PJ, El-Zeky F, Vander Zwaag R (1994) From Dukes through Jass. Pathological prognostic indicators in rectal cancer. Hum Pathol 25:498-505
15. 15. Jass JR, Sobin IH (eds) (1989) Histological typing of intestinal tumours, 2nd edn. Springer, Berlin Heidelberg New York, p 32
16. 16. Lamouse-Smith E, Clements VK, Ostrand-Rosenberg S (1993) B2M-/-knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection. J Immunol 151:6283-6290
17. 17. Lopez-Nevot M, Garcia E, Romero C, Oliva M, Serano S, Garrido F (1988) Phenotype and genetic analysis of HLA-class I and HLA-DR antigen expression on human melanomas. Exp Clin Immunogenet 5:203-212
18. 18. Moller P, Koretz K, Schlag P, Momburg F (1991) Frequency of abnormal expression of HLA-A, B, C and HLA-DR molecules, invariant chain, and LFA-3 (CD58) in colorectal carcinoma and its impact on tumor recurrence. Int J Cancer Suppl 6:155-162
19. 19. Newland RC, Chapius PH, Pheils MT, MacPherson JG (1981) The relationship of survival to staging and grading of colorectal carcinoma. A prospective study of 503 cases. Cancer 47:1424-1429
20. 20. Pardoll D (1993) New strategies for active immunotherapy with genetically engineered tumor cells. Curr Opin Immunol 4:719-725
21. 21. Roche PA, Cresswell P (1990) Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding. Nature 345:615-618
22. 22. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM (1997) Prognostic value of tumor-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182:318-324